IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $55.2B. The Maz Rating grades it against the other companies in its sector.
IDEXX Laboratories, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $700.65, IDEXX Laboratories, Inc. trades at 47.0x trailing earnings, 11.8x sales and 29.5x book value, with an EV/EBITDA of 33.5. Over the last twelve months it generated about $4.7B of revenue and $1.2B of net income. It runs a gross margin of 62.7%, an operating margin of 32.3% and a net margin of 25.4%. It shows return on equity of 71.2%, return on invested capital of 39.9% and a free cash flow yield of 2.4%. On the balance sheet: a debt-to-equity ratio of 0.52 and a current ratio of 1.19. Over the past 52 weeks the share price ranged from $500.61 to $769.98, with a beta of 1.54.
IDEXX Laboratories, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 13 Buy, 9 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, IDEXX Laboratories, Inc. (IDXX) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.89% / 30% · (Cash+Inv) / Mkt Cap (36m) 0.51% / 30% · Interest income / Revenue 0.08% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.89% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.44% / 33% · Receivables / Mkt Cap (36m) 1.37% / 49% · Interest income / Revenue 0.08% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.89% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.44% / 33.33% · Receivables / Mkt Cap (24m) 1.37% / 33.33% · Interest income / Revenue 0.08% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 27.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.58% / 33.33% · Receivables / Avg Assets (4Q) 19.8% / 33.33% · Interest income / Revenue 0.08% / 5% | Pass |
| FTSE | Debt / Total Assets 22.9% / 33.33% · (Cash+ST Inv) / Total Assets 5.33% / 33.33% · (Cash+Recv) / Total Assets 21.9% / 33.33% · Interest income / Revenue 0.08% / 5% | Pass |
Yes. As of September 2026, IDEXX Laboratories, Inc. (IDXX) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. IDEXX Laboratories, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.08% of each dividend: IDEXX Laboratories, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.